Do analysts rate TELA or KEQU?

TELA Bio currently has a consensus target price of $2.20, indicating a potential upside of 218.33%. Given TELA Bio's stronger consensus rating and higher probable upside, analysts plainly believe TELA Bio is more favorable than Kewaunee Scientific. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TELA Bio 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Kewaunee Scientific 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings and valuation, LNSR or TELA?

LENSAR has higher earnings, but lower revenue than TELA Bio. LENSAR is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LENSAR $58.44M 1.82 -$34.28M -$0.33 N/A TELA Bio $80.28M 0.39 -$38.83M -$0.77 N/A

Is LNSR or TELA more profitable?

LENSAR has a net margin of 57.57% compared to TELA Bio's net margin of -51.53%. LENSAR's return on equity of -529.08% beat TELA Bio's return on equity. Company Net Margins Return on Equity Return on Assets LENSAR 57.57% -529.08% 50.03% TELA Bio -51.53% -1,320.81% -59.39%

Is MBOT or TELA more profitable?

Microbot Medical has a net margin of 0.00% compared to TELA Bio's net margin of -51.53%. Microbot Medical's return on equity of -21.87% beat TELA Bio's return on equity. Company Net Margins Return on Equity Return on Assets Microbot Medical N/A -21.87% -20.76% TELA Bio -51.53% -1,320.81% -59.39%

Which has stronger valuation and earnings, TELA or LUNG?

TELA Bio has higher earnings, but lower revenue than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TELA Bio $80.28M 0.39 -$38.83M -$0.77 N/A Pulmonx $90.50M 1.19 -$54M -$1.16 N/A

Is TELA or LUNG more profitable?

TELA Bio has a net margin of -51.53% compared to Pulmonx's net margin of -55.03%. Pulmonx's return on equity of -96.66% beat TELA Bio's return on equity. Company Net Margins Return on Equity Return on Assets TELA Bio -51.53% -1,320.81% -59.39% Pulmonx -55.03% -96.66% -38.32%

Which has preferable earnings and valuation, HYPR or TELA?

Hyperfine has higher earnings, but lower revenue than TELA Bio. Hyperfine is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hyperfine $11.40M 8.08 -$35.57M -$0.38 N/A TELA Bio $80.28M 0.39 -$38.83M -$0.77 N/A

Is HYPR or TELA more profitable?

TELA Bio has a net margin of -51.53% compared to Hyperfine's net margin of -210.75%. Hyperfine's return on equity of -97.88% beat TELA Bio's return on equity. Company Net Margins Return on Equity Return on Assets Hyperfine -210.75% -97.88% -61.81% TELA Bio -51.53% -1,320.81% -59.39%

TELA Bio (TELA) Competitors

$0.69 -0.01 (-1.27%)

As of 04:00 PM Eastern

Compare

TELA vs. KEQU, LNSR, MBOT, LUNG, and HYPR

Should you buy TELA Bio stock or one of its competitors? TELA Bio's main competitors and comparable companies include Kewaunee Scientific (KEQU), LENSAR (LNSR), Microbot Medical (MBOT), Pulmonx (LUNG), and Hyperfine (HYPR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does TELA Bio compare to Kewaunee Scientific?

TELA Bio (NASDAQ:TELA) and Kewaunee Scientific (NASDAQ:KEQU) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

In the previous week, Kewaunee Scientific had 2 more articles in the media than TELA Bio. MarketBeat recorded 3 mentions for Kewaunee Scientific and 1 mentions for TELA Bio. TELA Bio's average media sentiment score of 0.94 beat Kewaunee Scientific's score of 0.87 indicating that TELA Bio is being referred to more favorably in the media.

Company	Overall Sentiment
TELA Bio	Positive
Kewaunee Scientific	Positive

94.4% of TELA Bio shares are held by institutional investors. Comparatively, 32.7% of Kewaunee Scientific shares are held by institutional investors. 5.1% of TELA Bio shares are held by company insiders. Comparatively, 14.1% of Kewaunee Scientific shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

TELA Bio currently has a consensus target price of $2.20, indicating a potential upside of 218.33%. Given TELA Bio's stronger consensus rating and higher probable upside, analysts plainly believe TELA Bio is more favorable than Kewaunee Scientific.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Kewaunee Scientific	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Kewaunee Scientific has a net margin of 3.41% compared to TELA Bio's net margin of -51.53%. Kewaunee Scientific's return on equity of 14.10% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TELA Bio	-51.53%	-1,320.81%	-59.39%
Kewaunee Scientific	3.41%	14.10%	5.55%

TELA Bio has a beta of 1.34, indicating that its share price is 34% more volatile than the broader market. Comparatively, Kewaunee Scientific has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market.

Kewaunee Scientific has higher revenue and earnings than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than Kewaunee Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TELA Bio	$80.28M	0.39	-$38.83M	-$0.77	N/A
Kewaunee Scientific	$282M	0.39	$9.62M	$3.22	11.76

Summary

Kewaunee Scientific beats TELA Bio on 9 of the 16 factors compared between the two stocks.

How does TELA Bio compare to LENSAR?

LENSAR (NASDAQ:LNSR) and TELA Bio (NASDAQ:TELA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

LENSAR has higher earnings, but lower revenue than TELA Bio. LENSAR is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENSAR	$58.44M	1.82	-$34.28M	-$0.33	N/A
TELA Bio	$80.28M	0.39	-$38.83M	-$0.77	N/A

In the previous week, LENSAR had 6 more articles in the media than TELA Bio. MarketBeat recorded 7 mentions for LENSAR and 1 mentions for TELA Bio. TELA Bio's average media sentiment score of 0.94 beat LENSAR's score of 0.87 indicating that TELA Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
LENSAR	Positive
TELA Bio	Positive

LENSAR has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market. Comparatively, TELA Bio has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market.

LENSAR has a net margin of 57.57% compared to TELA Bio's net margin of -51.53%. LENSAR's return on equity of -529.08% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENSAR	57.57%	-529.08%	50.03%
TELA Bio	-51.53%	-1,320.81%	-59.39%

40.2% of LENSAR shares are owned by institutional investors. Comparatively, 94.4% of TELA Bio shares are owned by institutional investors. 65.8% of LENSAR shares are owned by insiders. Comparatively, 5.1% of TELA Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

LENSAR currently has a consensus price target of $11.50, indicating a potential upside of 32.95%. TELA Bio has a consensus price target of $2.20, indicating a potential upside of 218.33%. Given TELA Bio's stronger consensus rating and higher possible upside, analysts plainly believe TELA Bio is more favorable than LENSAR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENSAR	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

LENSAR and TELA Bio tied by winning 8 of the 16 factors compared between the two stocks.

How does TELA Bio compare to Microbot Medical?

Microbot Medical (NASDAQ:MBOT) and TELA Bio (NASDAQ:TELA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

Microbot Medical has a net margin of 0.00% compared to TELA Bio's net margin of -51.53%. Microbot Medical's return on equity of -21.87% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Microbot Medical	N/A	-21.87%	-20.76%
TELA Bio	-51.53%	-1,320.81%	-59.39%

16.3% of Microbot Medical shares are owned by institutional investors. Comparatively, 94.4% of TELA Bio shares are owned by institutional investors. 4.7% of Microbot Medical shares are owned by company insiders. Comparatively, 5.1% of TELA Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Microbot Medical has higher earnings, but lower revenue than TELA Bio. Microbot Medical is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Microbot Medical	N/A	N/A	-$13.14M	-$0.24	N/A
TELA Bio	$80.28M	0.39	-$38.83M	-$0.77	N/A

In the previous week, Microbot Medical had 11 more articles in the media than TELA Bio. MarketBeat recorded 12 mentions for Microbot Medical and 1 mentions for TELA Bio. TELA Bio's average media sentiment score of 0.94 beat Microbot Medical's score of -0.64 indicating that TELA Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Microbot Medical	Negative
TELA Bio	Positive

Microbot Medical currently has a consensus price target of $6.38, suggesting a potential upside of 319.41%. TELA Bio has a consensus price target of $2.20, suggesting a potential upside of 218.33%. Given Microbot Medical's higher probable upside, equities analysts clearly believe Microbot Medical is more favorable than TELA Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Microbot Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Microbot Medical has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market. Comparatively, TELA Bio has a beta of 1.34, indicating that its stock price is 34% more volatile than the broader market.

Summary

Microbot Medical beats TELA Bio on 7 of the 13 factors compared between the two stocks.

How does TELA Bio compare to Pulmonx?

TELA Bio (NASDAQ:TELA) and Pulmonx (NASDAQ:LUNG) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

TELA Bio has higher earnings, but lower revenue than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TELA Bio	$80.28M	0.39	-$38.83M	-$0.77	N/A
Pulmonx	$90.50M	1.19	-$54M	-$1.16	N/A

TELA Bio has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market. Comparatively, Pulmonx has a beta of 0.28, meaning that its share price is 72% less volatile than the broader market.

TELA Bio has a net margin of -51.53% compared to Pulmonx's net margin of -55.03%. Pulmonx's return on equity of -96.66% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TELA Bio	-51.53%	-1,320.81%	-59.39%
Pulmonx	-55.03%	-96.66%	-38.32%

TELA Bio currently has a consensus target price of $2.20, suggesting a potential upside of 218.33%. Pulmonx has a consensus target price of $7.67, suggesting a potential upside of 206.67%. Given TELA Bio's higher probable upside, equities analysts plainly believe TELA Bio is more favorable than Pulmonx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Pulmonx	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Pulmonx had 1 more articles in the media than TELA Bio. MarketBeat recorded 2 mentions for Pulmonx and 1 mentions for TELA Bio. Pulmonx's average media sentiment score of 1.80 beat TELA Bio's score of 0.94 indicating that Pulmonx is being referred to more favorably in the news media.

Company	Overall Sentiment
TELA Bio	Positive
Pulmonx	Very Positive

94.4% of TELA Bio shares are held by institutional investors. Comparatively, 91.0% of Pulmonx shares are held by institutional investors. 5.1% of TELA Bio shares are held by company insiders. Comparatively, 7.5% of Pulmonx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Pulmonx beats TELA Bio on 8 of the 15 factors compared between the two stocks.

How does TELA Bio compare to Hyperfine?

Hyperfine (NASDAQ:HYPR) and TELA Bio (NASDAQ:TELA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

Hyperfine has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market. Comparatively, TELA Bio has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market.

TELA Bio has a net margin of -51.53% compared to Hyperfine's net margin of -210.75%. Hyperfine's return on equity of -97.88% beat TELA Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperfine	-210.75%	-97.88%	-61.81%
TELA Bio	-51.53%	-1,320.81%	-59.39%

Hyperfine presently has a consensus target price of $2.03, indicating a potential upside of 134.23%. TELA Bio has a consensus target price of $2.20, indicating a potential upside of 218.33%. Given TELA Bio's higher probable upside, analysts clearly believe TELA Bio is more favorable than Hyperfine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
TELA Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Hyperfine has higher earnings, but lower revenue than TELA Bio. Hyperfine is trading at a lower price-to-earnings ratio than TELA Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$11.40M	8.08	-$35.57M	-$0.38	N/A
TELA Bio	$80.28M	0.39	-$38.83M	-$0.77	N/A

In the previous week, Hyperfine had 6 more articles in the media than TELA Bio. MarketBeat recorded 7 mentions for Hyperfine and 1 mentions for TELA Bio. TELA Bio's average media sentiment score of 0.94 beat Hyperfine's score of 0.21 indicating that TELA Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Hyperfine	Neutral
TELA Bio	Positive

15.0% of Hyperfine shares are held by institutional investors. Comparatively, 94.4% of TELA Bio shares are held by institutional investors. 26.3% of Hyperfine shares are held by insiders. Comparatively, 5.1% of TELA Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Hyperfine and TELA Bio tied by winning 7 of the 14 factors compared between the two stocks.

Get TELA Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TELA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TELA vs. The Competition

Export

Metric	TELA Bio	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$31.43M	$5.94B	$7.40B	$12.81B
Dividend Yield	N/A	1.75%	2.53%	11.02%
P/E Ratio	-0.90	21.41	212.23	20.76
Price / Sales	0.39	69.39	630.33	94.71
Price / Cash	N/A	33.21	79.89	53.65
Price / Book	-1.97	6.24	13.14	6.20
Net Income	-$38.83M	$149.10M	$3.47B	$348.07M
7 Day Performance	6.82%	0.53%	1.38%	0.67%
1 Month Performance	0.01%	9.26%	8.62%	4.84%
1 Year Performance	-61.61%	6.82%	25.90%	16.83%

TELA Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TELA TELA Bio	3.416 of 5 stars	$0.69 -1.3%	$2.20 +218.3%	-61.7%	$31.43M	$80.28M	N/A	120	Gap Down
KEQU Kewaunee Scientific	1.2209 of 5 stars	$36.39 +0.2%	N/A	-33.2%	$104.44M	$282M	11.30	1,231	News Coverage Gap Up
LNSR LENSAR	3.0009 of 5 stars	$8.17 +1.0%	$11.00 +34.6%	-29.4%	$100.25M	$60.26M	N/A	110	Analyst Upgrade
MBOT Microbot Medical	1.9646 of 5 stars	$1.48 -2.0%	$6.38 +330.7%	-63.9%	$99.41M	N/A	N/A	20
LUNG Pulmonx	2.6858 of 5 stars	$2.29 +2.5%	$7.67 +235.4%	+49.7%	$98.35M	$87.44M	N/A	250	News Coverage Positive News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TELA) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TELA Bio (TELA) Competitors

TELA vs. KEQU, LNSR, MBOT, LUNG, and HYPR

How does TELA Bio compare to Kewaunee Scientific?

Summary

How does TELA Bio compare to LENSAR?

Summary

How does TELA Bio compare to Microbot Medical?

Summary

How does TELA Bio compare to Pulmonx?

Summary

How does TELA Bio compare to Hyperfine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELA vs. The Competition

TELA Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TELA Bio (TELA) Competitors

TELA vs. KEQU, LNSR, MBOT, LUNG, and HYPR

How does TELA Bio compare to Kewaunee Scientific?

Does the media favor TELA or KEQU?

Do institutionals and insiders believe in TELA or KEQU?

Do analysts rate TELA or KEQU?

Is TELA or KEQU more profitable?

Which has more volatility and risk, TELA or KEQU?

Which has higher earnings and valuation, TELA or KEQU?

Summary

How does TELA Bio compare to LENSAR?

Which has better earnings and valuation, LNSR or TELA?

Does the media prefer LNSR or TELA?

Which has more volatility & risk, LNSR or TELA?

Is LNSR or TELA more profitable?

Do institutionals & insiders hold more shares of LNSR or TELA?

Do analysts rate LNSR or TELA?

Summary

How does TELA Bio compare to Microbot Medical?

Is MBOT or TELA more profitable?

Do insiders & institutionals have more ownership in MBOT or TELA?

Which has stronger earnings and valuation, MBOT or TELA?

Does the media prefer MBOT or TELA?

Do analysts prefer MBOT or TELA?

Which has more risk & volatility, MBOT or TELA?

Summary

How does TELA Bio compare to Pulmonx?

Which has stronger valuation and earnings, TELA or LUNG?

Which has more volatility & risk, TELA or LUNG?

Is TELA or LUNG more profitable?

Do analysts recommend TELA or LUNG?

Does the media favor TELA or LUNG?

Do institutionals and insiders have more ownership in TELA or LUNG?

Summary

How does TELA Bio compare to Hyperfine?

Which has more volatility & risk, HYPR or TELA?

Is HYPR or TELA more profitable?

Do analysts rate HYPR or TELA?

Which has preferable earnings and valuation, HYPR or TELA?

Does the media refer more to HYPR or TELA?

Do institutionals & insiders believe in HYPR or TELA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELA vs. The Competition

TELA Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools